{"id":"remicade-infliximab","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Infections (including serious infections)"},{"rate":"5-10","effect":"Infusion reactions"},{"rate":"5-10","effect":"Headache"},{"rate":"5-8","effect":"Abdominal pain"},{"rate":"5-8","effect":"Nausea"},{"rate":"1-2","effect":"Tuberculosis reactivation"},{"rate":"low but increased","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, infliximab reduces the inflammatory cascade that drives autoimmune and inflammatory diseases. TNF-α is a central mediator of inflammation in conditions like rheumatoid arthritis, Crohn's disease, and psoriasis, so its neutralization suppresses disease activity and symptoms. This mechanism allows immune tolerance to be restored in these conditions.","oneSentence":"Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:25.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Plaque psoriasis"},{"name":"Behçet's disease"}]},"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT07237516","phase":"","title":"Zymfentra (Infliximab-dyyb) REal World Cohort STudy","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-20","conditions":"Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis","enrollment":200},{"nctId":"NCT07472309","phase":"","title":"Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-06-06","conditions":"Ulcerative Colitis (UC), Acute Severe Ulcerative Colitis, Upadacitinib","enrollment":81},{"nctId":"NCT07470502","phase":"NA","title":"MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-02-13","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":15},{"nctId":"NCT00606346","phase":"","title":"A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Biotech, Inc.","startDate":"2007-05-31","conditions":"Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis","enrollment":4970},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT04974099","phase":"PHASE2, PHASE3","title":"Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-10-01","conditions":"Crohn Disease","enrollment":6},{"nctId":"NCT04835506","phase":"PHASE4","title":"Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-11-01","conditions":"Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":124},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT07424040","phase":"NA","title":"The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-01","conditions":"Crohn's Diseases, Crohn's Disease in Pediatric Patient","enrollment":154},{"nctId":"NCT07417696","phase":"PHASE4","title":"Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Disease","enrollment":400},{"nctId":"NCT03907631","phase":"","title":"Multi-centre Acute Severe Ulcerative Colitis Prospective Cohort Study (Elevate ASUC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2019-10-18","conditions":"Severe Ulcerative Colitis","enrollment":189},{"nctId":"NCT07415473","phase":"PHASE4","title":"Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Diseases","enrollment":400},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05689879","phase":"PHASE3","title":"Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-23","conditions":"Sarcoidosis","enrollment":90},{"nctId":"NCT07385131","phase":"","title":"Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-08","conditions":"Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis","enrollment":300},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT02998398","phase":"","title":"Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-10","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease","enrollment":262},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT07314606","phase":"NA","title":"Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-15","conditions":"Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease","enrollment":140},{"nctId":"NCT01680159","phase":"PHASE3","title":"A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-07","conditions":"Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized)","enrollment":51},{"nctId":"NCT00691028","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":327},{"nctId":"NCT01585155","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-02","conditions":"Pediatric Ulcerative Colitis","enrollment":21},{"nctId":"NCT01580670","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-03","conditions":"Pediatric Crohn's Disease","enrollment":14},{"nctId":"NCT00805766","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":39},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT03885037","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Rheumatoid Arthritis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-20","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":"Immune-related Colitis","enrollment":""},{"nctId":"NCT07297069","phase":"PHASE2","title":"Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-01","conditions":"Acute Severe Ulcerative Colitis","enrollment":60},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT01630850","phase":"NA","title":"Islet Transplantation in Patients With \"Brittle\" Type I Diabetes","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT07263477","phase":"","title":"A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease (CD)","enrollment":900},{"nctId":"NCT07257068","phase":"NA","title":"Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-04-14","conditions":"Checkpoint Inhibitor, Pilot Study, Diabetes Melletus","enrollment":14},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT04898231","phase":"PHASE2, PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":"Multisystem Inflammatory Syndrome-Children","enrollment":73},{"nctId":"NCT05781152","phase":"PHASE4","title":"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","status":"RECRUITING","sponsor":"Connecticut Children's Medical Center","startDate":"2023-06-10","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT07176754","phase":"NA","title":"TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-10-01","conditions":"Cardiac Arrest (CA), Post Cardiac Arrest Syndrome","enrollment":208},{"nctId":"NCT05424926","phase":"","title":"Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-24","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":22},{"nctId":"NCT03684278","phase":"PHASE2","title":"Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2019-05-01","conditions":"Acute Pancreatitis","enrollment":290},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07120152","phase":"","title":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Erwin Dreesen","startDate":"2025-09-01","conditions":"IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis","enrollment":439},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn's Disease Relapse","enrollment":52},{"nctId":"NCT07149441","phase":"NA","title":"Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-08-01","conditions":"Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation","enrollment":94},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07123207","phase":"NA","title":"Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-04","conditions":"Mild to Severe Crohns Disease","enrollment":24},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT02638701","phase":"PHASE1, PHASE2","title":"Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-01","conditions":"Aneurysm, Stroke, Vasculitis","enrollment":8},{"nctId":"NCT00463580","phase":"PHASE4","title":"A Study of Infliximab for Treatment Resistant Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-12","conditions":"Depression","enrollment":60},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT03679546","phase":"PHASE4","title":"EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-01-04","conditions":"Ulcerative Colitis","enrollment":151},{"nctId":"NCT06660693","phase":"PHASE3","title":"Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-16","conditions":"Colitis, Ulcerative","enrollment":134},{"nctId":"NCT03885089","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Psoriasis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-21","conditions":"Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis","enrollment":10},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT05362630","phase":"","title":"Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2022-04-01","conditions":"Graft Versus Host Disease, Acute, Hematopoietic Stem Cell Transplantation","enrollment":28},{"nctId":"NCT05796245","phase":"","title":"A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-01","conditions":"Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease","enrollment":2207},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT06998797","phase":"","title":"Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-01","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT06995170","phase":"","title":"Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-01-01","conditions":"Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease","enrollment":146},{"nctId":"NCT05906576","phase":"PHASE4","title":"Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-09-21","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT03765450","phase":"","title":"Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2018-12-21","conditions":"Ulcerative Colitis","enrollment":18},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":172},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT06136546","phase":"PHASE2","title":"Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-01-23","conditions":"Depressive Disorder, Major, Inflammation","enrollment":100},{"nctId":"NCT06954311","phase":"","title":"Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2025-02-17","conditions":"Ulcerative Colitis (UC), IBD-unclassified (IBD-U)","enrollment":120},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT04312659","phase":"","title":"A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson (China) Investment Ltd.","startDate":"2020-07-15","conditions":"Crohn Disease","enrollment":38},{"nctId":"NCT02229344","phase":"","title":"Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2014-07-01","conditions":"Colitis, Ulcerative","enrollment":368},{"nctId":"NCT00741793","phase":"","title":"Biologic Treatment Registry Across Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2002-02-12","conditions":"Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic","enrollment":2821},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT05722353","phase":"NA","title":"IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-13","conditions":"Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT03884439","phase":"","title":"Infliximab Biosimilar \"Pfizer\" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-18","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":428},{"nctId":"NCT05313620","phase":"PHASE4","title":"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2022-04-01","conditions":"Ulcerative Colitis, Thromboembolism","enrollment":30},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT04331639","phase":"","title":"High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2020-11-01","conditions":"Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis","enrollment":50},{"nctId":"NCT06758024","phase":"NA","title":"PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-01-24","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":72},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT06839820","phase":"NA","title":"Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2025-02-01","conditions":"Infliximab, Infusion, IBD (Inflammatory Bowel Disease)","enrollment":60},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Remicade","SCH 215596"],"phase":"phase_3","status":"active","brandName":"Remicade (infliximab)","genericName":"Remicade (infliximab)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Remicade (infliximab) is a chimeric monoclonal antibody that inhibits tumor necrosis factor, a protein involved in inflammation. It is used to treat conditions such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, inflammatory bowel diseases, and psoriasis vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}